Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Flavio Vincenti
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Flavio Vincenti
I have been at UCSF since 1975 and on the faculty of the Department of Medicine in the division of Nephrology since 1976 and have been involved with the transplant service in patient care and clinical trials with novel immunosuppression drugs
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Merck Sharp & Dohme Corp.
- ID
- NCT03443869
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated